Literature DB >> 16627261

Vascular endothelial growth factor expression in the basal subtype of breast carcinoma.

Alfredo Ribeiro-Silva1, Fabiana Ribeiro do Vale, Sérgio Zucoloto.   

Abstract

The recognition of subtypes of breast carcinomas based on their molecular features has brought new perspectives in breast cancer research. Some key regulators of angiogenesis and tumor infiltration were evaluated in breast carcinomas of basal phenotype (cytokeratin [CK]5+). Immunohistochemical analysis with 14 primary antibodies was performed in 100 formalin-fixed, paraffin-embedded samples of invasive ductal carcinomas. CK5 correlated with indicators of poor outcome, including precocious age, high histologic grade, lymph node positivity, advanced pathologic stage, negativity for hormonal receptors, and a high proliferative rate (Ki-67 labeling index). CK5 also correlated with vascular endothelial growth factor (VEGF) expression but not with the microvessel density. Considering that VEGF-overexpressing neoplastic mammary cells display increased proliferative activity in vitro regardless of the angiogenic effect of VEGF, the differential expression of VEGF might contribute to the more aggressive behavior of these neoplasms. CK5 correlated with tissue inhibitor of metalloproteinase (TIMP)-1, but not matrix metalloproteinase (MMP)-1, MMP-2, extracellular matrix metalloproteinase inducer, TIMP-2 or plasminogen activator inhibitor, indicating that antiproteolytic stimuli might be preponderant in these neoplasms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16627261     DOI: 10.1309/D744-C4NM-15J3-B00D

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  10 in total

1.  Evaluation of Vascular Proliferation in Molecular Subtypes of Breast Cancer.

Authors:  Ionela Sevilla Bujor; Andreea Cioca; Raluca Amalia Ceaușu; Fulga Veaceslav; Cristian Nica; Anca Maria Cîmpean; Marius Raica
Journal:  In Vivo       Date:  2018 Jan-Feb       Impact factor: 2.155

Review 2.  Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.

Authors:  Olivier Trédan; Magali Lacroix-Triki; Séverine Guiu; Marie-Ange Mouret-Reynier; Jérôme Barrière; François-Clément Bidard; Antoine-Laurent Braccini; Olivier Mir; Christian Villanueva; Philippe Barthélémy
Journal:  Target Oncol       Date:  2014-09-05       Impact factor: 4.493

3.  Estimation of immunohistochemical expression of VEGF in ductal carcinomas of the breast.

Authors:  Else Maae; Martin Nielsen; Karina D Steffensen; Erik H Jakobsen; Anders Jakobsen; Flemming B Sørensen
Journal:  J Histochem Cytochem       Date:  2011-05-23       Impact factor: 2.479

4.  The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study.

Authors:  Ying Liu; Rulla M Tamimi; Laura C Collins; Stuart J Schnitt; Hannah L Gilmore; James L Connolly; Graham A Colditz
Journal:  Breast Cancer Res Treat       Date:  2011-03-09       Impact factor: 4.872

5.  Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez).

Authors:  Yousra Akasbi; Sanae Bennis; Fouad Abbass; Kawtar Znati; Khalid Amrani Joutei; Afaf Amarti; Omar El Mesbahi
Journal:  BMC Res Notes       Date:  2011-11-16

6.  Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial.

Authors:  Anna Goussia; Nafsika Simou; Flora Zagouri; Kyriaki Manousou; Georgios Lazaridis; Helen Gogas; Angelos Koutras; Maria Sotiropoulou; George Pentheroudakis; Dimitrios Bafaloukos; Christos Markopoulos; Helen Patsea; Christos Christodoulou; Pavlos Papakostas; Thomas Zaramboukas; Epaminontas Samantas; Paris Kosmidis; Vasileios Venizelos; Charisios Karanikiotis; George Papatsibas; Grigorios Xepapadakis; Konstantine T Kalogeras; Christina Bamia; Meletios-Athanassios Dimopoulos; Vassiliki Malamou-Mitsi; George Fountzilas; Anna Batistatou
Journal:  PLoS One       Date:  2018-07-31       Impact factor: 3.240

7.  Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.

Authors:  Praveenkumar K Shetty; Sanjay I Thamake; Swati Biswas; Sonny L Johansson; Jamboor K Vishwanatha
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

Review 8.  Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials.

Authors:  Elham Fakhrejahani; Masakazu Toi
Journal:  Jpn J Clin Oncol       Date:  2014-01-27       Impact factor: 3.019

9.  Biomarkers for Basal-like Breast Cancer.

Authors:  Jennifer R Choo; Torsten O Nielsen
Journal:  Cancers (Basel)       Date:  2010-05-28       Impact factor: 6.639

10.  Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer.

Authors:  Hawa Nalwoga; Lavina Ahmed; Jarle B Arnes; Henry Wabinga; Lars A Akslen
Journal:  PLoS One       Date:  2016-01-13       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.